Lietuva -
lietuviešu -
SMCA (Valstybinė vaistų kontrolės tarnyba)
multibic be kalio
fresenius medical care deutschland gmbh - natrio-vandenilio karbonatas/magnio chloridas heksahidratas/natrio chloridas/kalcio chloridas dihidratas/gliukozė - hemodializės ar hemofiltracijos tirpalas - 2,94 g/6,136 g/0,2237 g/0,2205 g/0,1017 g/1 g/1000 ml; 2,94 g/0,2205 g/0,1017 g/1 g/6,136 g/0,2982 g/1000 ml; 2,94 g/0,1017 g/6,136 g/0,2205 g/1 g/1000 ml; 2,94 g/6,136 g/0,1491 g/0,2205 g/0,1017 g/1 g/1000 ml; 2,94 g/6,136 g/0,2237 g/0,2 - hemofiltrates
Eiropas Savienība -
lietuviešu -
EMA (European Medicines Agency)
yescarta
kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - antinavikiniai vaistai - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.
Eiropas Savienība -
lietuviešu -
EMA (European Medicines Agency)
idefirix
hansa biopharma ab - imlifidase - desensitization, immunologic; kidney transplantation - imunosupresantai - idefirix is indicated for desensitisation treatment of highly sensitised adult kidney transplant patients with positive crossmatch against an available deceased donor. the use of idefirix should be reserved for patients unlikely to be transplanted under the available kidney allocation system including prioritisation programmes for highly sensitised patients.
Eiropas Savienība -
lietuviešu -
EMA (European Medicines Agency)
rybrevant
janssen-cilag international n.v. - amivantamab - karcinoma, nesmulkiųjų ląstelių skausmas - antinavikiniai vaistai - rybrevant as monotherapy is indicated for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating epidermal growth factor receptor (egfr) exon 20 insertion mutations, after failure of platinum-based chemotherapy.
Lietuva -
lietuviešu -
Adama
legacy® pro
adama - koncentruota suspensija - chlorotoluronas + diflufenikanas + pendimetalinas - herbicidai
Lietuva -
lietuviešu -
Adama
seedron®
adama - takus koncentratas - fludioksonilas + tebukonazolas - beicai